Autopsy report · NCT01180764

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

“Withdrawn for administrative reasons.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

University of Utah

Sponsor type

University, hospital or other

Conditions

Hypertriglyceridemia

Interventions

Lovaza (Omega-3 acid ethyl esters); Placebo

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• MAGIK for Femoral/Tibial Shaft Fractures
  “Withdrawn due to lack of funding.” (84% match in meaning)
• The Effect of Light Therapy on Post-Surgical Pain
  “Withdrawn due to lack of resources” (73% match in meaning)
• Hydroxychloroquine Efficacy in Chronic Urticaria
  “withdrawn, not funded” (73% match in meaning)
• Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
  “Withdrawn due to low accrual” (72% match in meaning)
• Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk
  “Withdrawn due to poor accrual” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.